Skip to main content
Clinical Trials/NCT03470155
NCT03470155
Completed
Not Applicable

Operative Mitralklappenrekonstruktion Bei Funktionellen Mitralklappenvitien Bei Reduzierter Systolischer Ventrikelfunktion

Institut für Pharmakologie und Präventive Medizin6 sites in 1 country105 target enrollmentJune 5, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mitral Valve Insufficiency
Sponsor
Institut für Pharmakologie und Präventive Medizin
Enrollment
105
Locations
6
Primary Endpoint
recurrent mitral valve insufficiency > grade 2
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Functional mitral insufficiency poses a challenge with regard to the optimal time of intervention, particularly because they are frequently associated with left ventricular (LV) dilation and reduced LV ejection fraction (EF). The registry will document the underlying pathology by using transthoracal echo cardiography (TTE) with analysis of common tenting parameters. OP strategies, data and outcomes will be documented, as well as follow-up data for echocardiography, quality of life and MACCE outcomes after 6 months, 1 and 2 years.

Detailed Description

Prospective enrolment of all patients with mitral valve insufficiency and restricted movement of leaflets during systole into a multicentric registry. Exact analysis of the underlying pathology using TTE with analysis of tenting parameters. In patients without contraindications, functional preoperative MRT to determine the functional reserve of ventricular function. Documentation of the quality of life of the patients using the SF12 questionnaire before and after intervention. Documentation of follow-up data (SF12, TTE, NT-pro BNP) at 6 months, 1 and 2 years. Development of operative strategies to improve long-term outcomes in patients with severe LV dilation (typically accompanied by function mitral insufficiency type IIIb).

Registry
clinicaltrials.gov
Start Date
June 5, 2018
End Date
July 31, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Institut für Pharmakologie und Präventive Medizin
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • functional mitral valve insufficiency with reduced mobility of leaflets during systole (type IIIb) - effective regurgitation orifice area \> 20 mm2 / regurgitant volume \> 30 ml/beat
  • left ventricular ejection fraction \<= 50% and /or left ventricular end-diastolic diameter \>= 60 mm
  • tenting of the proximal and / or anterior mitral leaflets

Exclusion Criteria

  • prolaps of leaflets (type II mitral regurgitation)
  • combination intervention with aortic valve repair or replacement
  • re-operation at mitral valve

Outcomes

Primary Outcomes

recurrent mitral valve insufficiency > grade 2

Time Frame: 2 years

see above

Secondary Outcomes

  • MACCE(1 year)
  • re-intervention at mitral valve(2 years)
  • cardiovascular mortality(2 years)
  • device therapy (e. g. left ventricular auxiliary device or heart transplant) due to progressive heart failure(2 years)
  • re-hospitalisation due to heart failure(2 years)

Study Sites (6)

Loading locations...

Similar Trials